Emmanuel Oisakede, Academic Clinical Fellow Resident at Leeds Teaching Hospitals NHS Trust, shared a post on LinkedIn:
“What happens when someone living with HIV is diagnosed with cancer in sub-Saharan Africa?
Is timely cancer treatment accessible? Can patients afford to complete treatment? And how well are HIV and oncology services working together?
These were some of the questions that motivated our latest research.
I am delighted to share the publication of our recent paper in Infectious Disease Reports:
Management of HIV-Associated Cancers in Sub-Saharan Africa: A Scoping Review of Treatment Outcomes, Challenges, and Strategies for Enhancing Care.’
We focused on SSA, and synthesised evidence from 51 publications across 10 countries, examining cancer treatment approaches, clinical outcomes, barriers to care and potential strategies for improvement.
One finding particularly stood out to me!
The success of cancer treatment cannot be judged only by outcomes among patients who receive it. We must also account for those who never reach treatment or cannot complete it.
As a clinician and researcher with roots in Africa, I believe our responsibility goes beyond identifying gaps in healthcare. We must generate evidence that can inform practical, locally appropriate solutions.
For SSA, improving cancer outcomes among people living with HIV will require stronger oncology services, better coordination with HIV care, and research that reflects the realities of patients navigating these healthcare systems.
I am grateful to my co-authors and collaborators for their contributions to this work.”
Title: Management of HIV-Associated Cancers in Sub-Saharan Africa: A Scoping Review of Treatment Outcomes, Challenges, and Strategies for Enhancing Care
Authors: Emmanuel O. Oisakede, Daniel Asogun, Ayobami T. Adegbenro, Godwin-Uzor Treasure Chinazaekpere, Jane Iguma-Asaka, Onoyemeh Hope Adams, Augustina Konadu Larbi-Ampofo, Ehimemen Stacy Aigbokhaevbo
Read the Full Article on Infectious Disease Reports
You can also read: Shikha Jain: What Does Paul Rubinstein’s Work Mean for Patients with HIV and Cancer?